Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Buparlisib (Primary) ; Paclitaxel
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms BERIL-1
- Sponsors Novartis Pharmaceuticals
- 24 Jun 2017 This trial has been discontinued in Ireland (End date:2017-03-30) as per European Clinical Trials Database record.
- 15 Jun 2017 Status changed from active, no longer recruiting to completed.
- 03 Jun 2017 This trial has been discontinued in Germany (End date:2017-03-30) as per European Clinical Trials Database record.